Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + camrelizumab + CAPOX neoadjuvant study in locally advanced gastric/GEJ adenocarcinoma
ChiCTR2400088196Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, camrelizumab, capecitabine and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Affiliated Hospital of North Sichuan Medical College. Primary endpoint: Pathological complete response rate. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
Rivoceranibcamrelizumabcapecitabineoxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400088196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088196.